Transarterial chemoembolization using drug eluting microspheres in refractory colorectal liver metastases with 18F-FDG PET/CT follow-up to assess therapeutic response

Mansour, Mohamed G.; Ali, Susan Adil

doi:10.1016/j.ejrnm.2016.09.014

Cited by 7 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 F-FDG PET/CT is a nonspecific nuclear imaging tool, used mainly for oncologic patients for the detection and staging of many malignant tumors [ 18 – 20 ]. It is also used for the follow-up of cancer patients [ 21 – 23 ]. 18 F-FDG PET/CT is an efficient tool to assess response to treatment of different tumors [ 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

Incidentally recognized COVID-19 pneumonia in routine oncologic 18F-FDG PET/CT examinations: a local experience during pandemic era

Ali

Abdelkawi

2020

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background CT chest findings of COVID-19 pneumonia can be detected before the clinical symptoms become evident in many cases. In this work, we presented our experience in incidental detection of COVID-19-associated pneumonia in asymptomatic patients coming for routine oncologic 18F-FDG PET/CT examinations during the COVID-19 pandemic, which contribute in the detection of the affected patients early to be isolated and properly managed. We reported the cases with incidental finding of COVID-19 pneumonia among 764 asymptomatic patients who were referred for whole-body 18F-FDG PET/CT examinations for routine oncologic indications in the period between 15 March and 15 June 2020, and RT-PCR testing for them was requested for confirmation. Results Among the 764 scanned patients, we had recognized 87 patients (11.3%) having features of COVID-19 pneumonia. RT-PCR testing of them confirmed COVID-19 infection in 78 cases, yet 3 were negative and no RT-PCR testing was performed in 6 cases (only isolated and carefully monitored). Conclusion 18F-FDG PET/CT is sensitive for early COVID-19 detection, even in asymptomatic patients that guide proper management and also highlight the key role of a radiologist and the importance of applying safety measures in clinical services during the pandemic to minimize the spread of infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidentally recognized COVID-19 pneumonia in routine oncologic 18F-FDG PET/CT examinations: a local experience during pandemic era

Ali

Abdelkawi

2020

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

show abstract

“…However, significant advances in structural and functional imaging during the past two decades lead to improvement in evaluation of the treatment response [16]. 18 F-FDG PET/CT can quickly and efficiently assess malignant tumor response to treatment, including breast cancer, by comparing baseline scan prior to and following 1 or 2 cycles of treatment [17][18][19][20][21][22]. It can demonstrate metabolic changes (much earlier than morphological changes in conventional imaging modalities) semi-quantitatively by calculating the SUV max which indicates the 18F-FDG uptake [23].…”

Section: Discussionmentioning

confidence: 99%

“…This prospective study was conducted in the period from March 2017 to October 2019 and included 30 female patients with locally advanced breast cancer (a total of 31 lesions) who were referred to perform baseline pretreatment and end of therapy 18 F-FDG PET/CT scans (before starting and after completion of NAC). Approval of the institutional review board and written informed consents from all patients was obtained before the start of this study.…”

Section: Patientsmentioning

confidence: 99%

“…It has been used to evaluate the clinical response to NAC in breast cancer patients because metabolic reduction often occurs early in the course of therapy and precedes reduction in size of the tumor. Semiquantitative assessment of 18 F-FDG uptake has been reported as a strong predictor of pathologic and clinical response. Metabolic reduction detected before and after NAC using PERCIST (PET Response Criteria In Solid Tumor) can provide early information on potential tumor response [4].…”

Section: Introductionmentioning

confidence: 99%

“…Metabolic reduction detected before and after NAC using PERCIST (PET Response Criteria In Solid Tumor) can provide early information on potential tumor response [4]. The aim of this work was to assess the added value of 18 F-FDG PET/CT scan in evaluation of response to neoadjuvant chemotherapy in locally advanced breast cancer patients before surgery.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Role of 18 fluorine-fluorodeoxyglucose positron emission tomography/computed tomography in assessment of neoadjuvant chemotherapy response in breast cancer patients

Sarhan¹,

Gohary

Moneim

et al. 2020

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background: Neoadjuvant chemotherapy (NAC) is a therapeutic option for locally advanced breast cancer and is aiming to reduce tumor volume for breast conservation. Accurate assessment of residual tumor after NAC is a crucial for determining the outcome and survival of the patients. Eighteen fluorine-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) has been recently used as a reliable tool to evaluate response to treatment due to combined morphologic and metabolic information. The aim of this study was to assess the value of 18 F-FDG PET/CT in evaluation of response to NAC in a sample size of recently diagnosed 30 locally advanced breast cancer patients, who were referred for 18 F-FDG PET/CT scanning before and after NAC. The morphologic and metabolic response was evaluated and compared to histopathologic findings. Results: 18 F-FDG PET/CT detected 23 responders and 7 non-responders among the examined 30 breast cancer patients, compared to 20 responders and 10 non-responders detected by CT alone. 18 F-FDG PET/CT showed sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 95.5%, 75%, 91.3, 85.7, and 90%, respectively, compared to 81.8%, 75%, 90, 60, and 80%, respectively, achieved by CT alone. Conclusion: 18 F-FDG PET/CT is a reliable single whole body imaging tool which can be used in monitoring of NAC response in patients with locally advanced breast cancer showing higher sensitivity and accuracy compared to CT alone.

show abstract

Nuclear medicine and radiopharmaceuticals for molecular diagnosis

Özdemir

Gündoğdu

Ekinci

et al. 2019

Biomedical Applications of Nanoparticles

View full text Add to dashboard Cite

Transarterial chemoembolization using drug eluting microspheres in refractory colorectal liver metastases with 18F-FDG PET/CT follow-up to assess therapeutic response

Cited by 7 publications

References 13 publications

Incidentally recognized COVID-19 pneumonia in routine oncologic 18F-FDG PET/CT examinations: a local experience during pandemic era

Incidentally recognized COVID-19 pneumonia in routine oncologic 18F-FDG PET/CT examinations: a local experience during pandemic era

Role of 18 fluorine-fluorodeoxyglucose positron emission tomography/computed tomography in assessment of neoadjuvant chemotherapy response in breast cancer patients

Nuclear medicine and radiopharmaceuticals for molecular diagnosis

Contact Info

Product

Resources

About